Top Stories

CureVac COVID-19 vaccine records only 48% efficacy in final trial readout

Published by maria gbaf

Posted on July 1, 2021

· Last updated: January 21, 2026

Add as preferred source on Google
Dose of CureVac COVID-19 vaccine showcased in clinical trial setting - Global Banking & Finance Review
This image depicts a dose of the CureVac COVID-19 vaccine, relevant to the recent report on its 48% efficacy in final trials. The visual emphasizes the clinical trial aspect of vaccine development.
Global Banking & Finance Awards 2026 — Call for Entries

Related Articles

More from Top Stories

Explore more articles in the Top Stories category